Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Part of paid clinical trials in Palo Alto, California.

Sponsor: Stanford University
Study ID: NCT03582124
Phase: PHASE1/PHASE2
Status: Recruiting

Apply to this trial

Conditions

Lung Carcinoma
Metastatic Malignant Neoplasm in the Lung
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Eligibility Criteria

Sex: ALL
Age: 19 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Near-Infrared Fluorescence Imaging — PROCEDURE
Undergo imaging
Panitumumab-IRDye800 — DRUG
Given IV
Pharmacokinetic Study — OTHER
Correlative studies
Therapeutic Conventional Surgery — PROCEDURE
Undergo surgery

Study Details

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Key Dates

First listed: Jul 10, 2018
Start date: Jul 19, 2018
Status verified: Feb 2026
Primary completion: Sep 30, 2026
Completion: Sep 30, 2026

Study Design

Enrollment: 30 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Arms

Experimental: Diagnostic (panitumumab-IRDye800, surgery, NIR)
Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.